Rafael Diaz1, Kord M Kober1, Carol Viele1, Bruce A Cooper1, Steven M Paul1, Marilyn Hammer2, Fay Wright3, Yvette P Conley4, Jon D Levine5, Christine Miaskowski6,7. 1. School of Nursing, University of California, San Francisco, CA, USA. 2. Dana Farber Cancer Center, Boston, MA, USA. 3. Rory Meyers College of Nursing, New York University, New York, NY, USA. 4. School of Nursing, University of Pittsburgh, Pittsburgh, PA, USA. 5. School of Medicine, University of California, San Francisco, CA, USA. 6. School of Nursing, University of California, San Francisco, CA, USA. chris.miaskowski@ucsf.edu. 7. Department of Physiological Nursing, University of California, 2 Koret Way - N631Y, San Francisco, CA, 94143-0610, USA. chris.miaskowski@ucsf.edu.
Abstract
PURPOSE: Chemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50 to 80% of patients. Given that the majority of the data on the occurrence and severity of CID is based on physician-rated toxicity criteria, this study's purposes were to identify subgroups of patients with distinct CID profiles and determine how these subgroups differ in terms of demographic and clinical characteristics; severity, frequency, and distress of CID; the co-occurrence of common GI symptoms; and QOL. METHODS: Patients (n = 1133) completed the Memorial Symptom Assessment Scale six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct diarrhea profiles. Differences among these subgroups were evaluated using parametric and nonparametric statistics. RESULTS: Four distinct diarrhea profiles were identified: none (58.3%), decreasing (22.0%), increasing (5.2%), and high (14.5%). Compared with the none class, patients in the high class had a lower functional status, a worse comorbidity profile, were more likely to have gastrointestinal cancer, and were more likely to receive chemotherapy on a 14-day cycle. No differences were found among the classes in the percentages of patients who received chemotherapy with a targeted therapy. CONCLUSION: Given that CID occurred in over 40% of the patients, clinicians should assess for this symptom and other common GI symptoms and initiate appropriate pharmacologic and dietary interventions.
PURPOSE: Chemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50 to 80% of patients. Given that the majority of the data on the occurrence and severity of CID is based on physician-rated toxicity criteria, this study's purposes were to identify subgroups of patients with distinct CID profiles and determine how these subgroups differ in terms of demographic and clinical characteristics; severity, frequency, and distress of CID; the co-occurrence of common GI symptoms; and QOL. METHODS:Patients (n = 1133) completed the Memorial Symptom Assessment Scale six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct diarrhea profiles. Differences among these subgroups were evaluated using parametric and nonparametric statistics. RESULTS: Four distinct diarrhea profiles were identified: none (58.3%), decreasing (22.0%), increasing (5.2%), and high (14.5%). Compared with the none class, patients in the high class had a lower functional status, a worse comorbidity profile, were more likely to have gastrointestinal cancer, and were more likely to receive chemotherapy on a 14-day cycle. No differences were found among the classes in the percentages of patients who received chemotherapy with a targeted therapy. CONCLUSION: Given that CID occurred in over 40% of the patients, clinicians should assess for this symptom and other common GI symptoms and initiate appropriate pharmacologic and dietary interventions.
Entities:
Keywords:
Cancer; Chemotherapy; Diarrhea; Latent class analysis; Quality of life
Authors: Stephen H Rosenoff; Nashat Y Gabrail; Richard Conklin; John A Hohneker; William J Berg; Ghulam Warsi; Jennifer Maloney; John J Benedetto; Elizabeth A Miles; Wei Zhu; Lowell Anthony Journal: J Support Oncol Date: 2006-06
Authors: Komal Singh; Keenan Pituch; Qiyun Zhu; Haiwei Gu; Brenda Ernst; Cindy Tofthagen; Melanie Brewer; Kord M Kober; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022-03-02 Impact factor: 2.760
Authors: H R Wardill; C E M de Mooij; A R Da Silva Ferreira; H Havinga; H J M Harmsen; W J F M van der Velden; L F J van Groningen; W J E Tissing; N M A Blijlevens Journal: Sci Rep Date: 2022-05-11 Impact factor: 4.996